There is no literature regarding the risk of a patient developing PJI after primary TKA if the patient has previously experienced PJI of a TKA or THA in another joint. The goal of this study was to compare the risk of PJI of primary TKA in this patient population compared to matched controls. We retrospectively reviewed 95 patients (102 primary TKAs) from 2000–2014 with a history of a TKA or THA PJI in another joint. Mean age was 69 years; mean BMI was 36 kg/m2. 27% high-risk patients were on chronic antibiotic suppression. Mean follow-up was 6 years. We 1:3 matched (to age, sex, BMI, and surgical year) these to 306 primary TKAs performed in patients with a THA or TKA of another joint without a subsequent PJI. Competing risk with death was used for statistical analysis. Multivariate analysis was utilized to evaluate risk factors for PJI in the study cohort.Introduction
Methods
Abstract. Aims. The primary aim of this study was to evaluate the outcomes of fungal
Introduction. Our objective is to describe early and midterm results with the use of a new knee prosthesis as an articulating spacer in planned two-stage management for infected total knee arthroplasty. As a second objective, we compared outcomes between the group with a retained first stage and those with a completed 2-stage revision. Methods. Forty-seven patients (48 knees) from January 2012 and November 2017 underwent a 2-stage exchange with an articulating spacer with new implants was used for a chronic